Journal of Clinical Oncology, Vol 15, 2691-2700, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

MJ McKeage, F Raynaud, J Ward, C Berry, D O'Dell, LR Kelland, B Murrer, P Santabarabara, KR Harrap and IR Judson
Cancer Research Campaign Centre of Cancer Therapeutics, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

PURPOSE: We aimed to determine the maximum-tolerated dose (MTD) clinical toxicities, pharmacokinetics, and pharmacodynamics of oral JM216 given once daily for 5 days to cancer patients. PATIENTS AND METHODS: Patients who fulfilled standard phase I trial criteria were enrolled. Oral JM216 was given at doses based on patient body-surface area, on an empty stomach, once daily for 5 consecutive days, as 10-, 50-, and 200-mg hard gelatin capsules and with oral antiemetics. The pharmacokinetics of platinum were studied on days 1 and 5 of the first treatment course using atomic absorption spectrophotometry (AAS). RESULTS: Thirty-two patients received 94 courses of oral JM216 at doses that ranged from 30 to 140 mg/m2 body-surface area for 5 consecutive days. The MTD was 140 mg/m2/d. The dose-limiting toxicities were thrombocytopenia and neutropenia. Hematotoxicity was reversible (nadir, 17 to 21 days; recovery, 28 days), noncumulative, and dependent on the dose and history of previous therapy. There were two instances of neutropenic sepsis. Two-thirds of patients experienced mild nausea, vomiting, or diarrhea. There was no ototoxicity, neurotoxicity, nephrotoxicity, or objective tumor responses. There was a significant correlation between JM216 dose and the day 1 and 5 plasma ultrafiltrate area under the concentration-time curve (AUC; r = .78), which indicates linear pharmacokinetics. There was considerable intersubject pharmacokinetic and pharmacodynamic variability, but a significant sigmoidal relationship between the plasma ultrafiltrate AUC and severity of thrombocytopenia (R2 = .83). CONCLUSION: We recommend JM216 doses of 100 and 120 mg/m2/d x 5 for previously treated and untreated patients, respectively, for phase II trials.

This article has been cited by other articles:

				H. Choy, C. Park, and M. Yao Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue Clin. Cancer Res., March 15, 2008; 14(6): 1633 - 1638. [Abstract] [Full Text] [PDF]

				D. R. Berthold, C. N. Sternberg, and I. F. Tannock Management of Advanced Prostate Cancer After First-Line Chemotherapy J. Clin. Oncol., November 10, 2005; 23(32): 8247 - 8252. [Abstract] [Full Text] [PDF]

				T. Kurata, T. Tamura, Y. Sasaki, H. Fujii, S. Negoro, M. Fukuoka, and N. Saijo Pharmacokinetic and Pharmacodynamic Analysis of Bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) Administered Once a Day for Five Consecutive Days: A Phase I Study Jpn. J. Clin. Oncol., September 1, 2000; 30(9): 377 - 384. [Abstract] [Full Text] [PDF]

				E. Fokkema, H. J.M. Groen, J. Bauer, D. R.A. Uges, C. Weil, and I. E. Smith Phase II Study of Oral Platinum Drug JM216 as First-Line Treatment in Patients With Small-Cell Lung Cancer J. Clin. Oncol., December 1, 1999; 17(12): 3822 - 3827. [Abstract] [Full Text] [PDF]

				L. B. Travis, E. J. Holowaty, K. Bergfeldt, C. F. Lynch, B. A. Kohler, T. Wiklund, R. E. Curtis, P. Hall, M. Andersson, E. Pukkala, et al. Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer N. Engl. J. Med., February 4, 1999; 340(5): 351 - 357. [Abstract] [Full Text] [PDF]